These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37337751)

  • 1. Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma.
    Puckrin R; Owen C; Street L; Perry S; Peters A; Stewart D
    Leuk Lymphoma; 2023 Sep; 64(9):1596-1599. PubMed ID: 37337751
    [No Abstract]   [Full Text] [Related]  

  • 2. Bendamustine-rituximab in mantle cell lymphoma.
    Lipsky A; Martin P
    Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
    [No Abstract]   [Full Text] [Related]  

  • 3. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
    Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
    Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
    Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
    Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
    Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Bouabdallah K; Khanal R; Topp MS; Houot R; Beitinjaneh A; Peng W; Fang X; Shen RR; Siddiqi R; Kloos I; Reagan PM
    J Clin Oncol; 2023 Jan; 41(3):555-567. PubMed ID: 35658525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
    Du KX; Shen HR; Wang L; Liang JH; Wu JZ; Li Y; Xia Y; Yin H; Li JY; Xu W
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):333-336. PubMed ID: 37357004
    [No Abstract]   [Full Text] [Related]  

  • 8. Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
    Hui M; Chen M
    Ann Hematol; 2022 Apr; 101(4):911-913. PubMed ID: 34487230
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    McCulloch R; Visco C; Eyre TA; Frewin R; Phillips N; Tucker DL; Quaglia FM; McMillan A; Lambert J; Crosbie N; Rule S
    Br J Haematol; 2020 May; 189(4):684-688. PubMed ID: 32011729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2.
    Wang M; Jain P; Chi TL; Chen SE; Heimberger A; Weathers SP; Zheng L; Rao AV; Rossi JM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma.
    Schalk E; Jentsch-Ullrich K
    Ann Hematol; 2023 Jun; 102(6):1617-1620. PubMed ID: 36928308
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
    Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
    Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
    Hagiwara K; Tokunaga T; Iida H; Nagai H
    Anticancer Res; 2015 Dec; 35(12):6679-84. PubMed ID: 26637884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing of Novel Therapies for Mantle Cell Lymphoma.
    Romancik JT; Cohen JB
    Curr Treat Options Oncol; 2021 Nov; 22(12):118. PubMed ID: 34812968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
    Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report.
    Ettleson M; Bongers KS; Vitale K; Perissinotti AJ; Phillips T; Marini BL
    J Oncol Pharm Pract; 2019 Apr; 25(3):731-734. PubMed ID: 29385883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
    Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
    Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
    [No Abstract]   [Full Text] [Related]  

  • 19. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
    Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
    Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
    Albertsson-Lindblad A; Palsdottir T; Smedby KE; Weibull CE; Glimelius I; Jerkeman M
    Haematologica; 2022 Mar; 107(3):740-743. PubMed ID: 34788983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.